Chemomab Therapeutics Ltd DRC (CMMB) — Cash Flow-to-Debt Ratio
Chemomab Therapeutics Ltd DRC (CMMB) has a Cash Flow-to-Debt Ratio of -7.59x as of December 2025, meaning its operating cash flow of $-11.22 Million could theoretically repay -8% of its total liabilities ($1.48 Million) in one year. Explore Chemomab Therapeutics Ltd DRC (CMMB) investment intensity to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Chemomab Therapeutics Ltd DRC Cash Flow-to-Debt Ratio (2015–2025)
Historical debt coverage capacity for Chemomab Therapeutics Ltd DRC across 11 annual periods. Also explore Chemomab Therapeutics Ltd DRC asset portfolio for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Chemomab Therapeutics Ltd DRC (2015–2025)
Year-by-year debt coverage analysis for Chemomab Therapeutics Ltd DRC. For market capitalisation and broader financial context, see how much is Chemomab Therapeutics Ltd DRC worth.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -7.59x | $-11.22 Million | $1.48 Million | ▼ -68.3% |
| 2024 | -4.51x | $-15.46 Million | $3.43 Million | ▲ +1.3% |
| 2023 | -4.57x | $-23.55 Million | $5.15 Million | ▼ -54.0% |
| 2022 | -2.97x | $-20.29 Million | $6.84 Million | ▲ +30.8% |
| 2021 | -4.29x | $-12.38 Million | $2.89 Million | ▲ +43.9% |
| 2020 | -7.65x | $-12.80 Million | $1.67 Million | ▼ -124.4% |
| 2019 | -3.41x | $-16.51 Million | $4.85 Million | ▲ +29.0% |
| 2018 | -4.80x | $-14.18 Million | $2.96 Million | ▼ -50.7% |
| 2017 | -3.18x | $-8.58 Million | $2.70 Million | ▼ -100.8% |
| 2016 | -1.59x | $-3.74 Million | $2.36 Million | ▲ +70.6% |
| 2015 | -5.38x | $-7.38 Million | $1.37 Million | — |